Sacituzumab govitecan safe and significantly beneficial over chemotherapy in treating metastatic breast cancer
According to a recent study, sacituzumab govitecan was safe and significantly beneficial over chemotherapy in treating metastatic breast cancer. This study's result were published in the journal, Lancet.
The TROPiCS-02 was a randomized, phase 3, multi-centre, open-label trial that included 543 patients with confirmed hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ and HER2-). They were randomly assigned in a 1:1 ratio to receive either sacituzumab govitecan (n=272) or chemotherapy (n=271; eribulin, vinorelbine, capecitabine, or gemcitabine). The patients had received at least one previous endocrine therapy, a taxane, as well as a CDK4/6 inhibitor in any setting and 2-4 previous chemotherapy regimens for metastatic disease. The study's primary endpoint was progression-free survival while the secondary endpoints included objective response rate (ORR), overall survival, and patient-reported outcomes.
At the end of the study, it was observed that sacituzumab govitecan significantly improved overall survival. Also, ORR was significantly improved with sacituzumab govitecan as was time to deterioration of global health status and quality of life. The safety profile of sacituzumab govitecan was in accordance with those of the ASCENT trial and primary analysis of TROPiCS-02.
Based on the results of this study, it can be concluded that sacituzumab govitecan may be used as a new treatment option for patients with pretreated metastatic breast cancer as it may demonstrate statistically significant and clinically meaningful benefits with a manageable safety profile.
Sacituzumab govitecan safe and significantly beneficial over chemotherapy in treating metastatic breast cancer
According to a recent study, sacituzumab govitecan was safe and significantly beneficial over chemotherapy in treating metastatic breast cancer. This study's result were published in the journal, Lancet.
The TROPiCS-02 was a randomized, phase 3, multi-centre, open-label trial that included 543 patients with confirmed hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ and HER2-). They were randomly assigned in a 1:1 ratio to receive either sacituzumab govitecan (n=272) or chemotherapy (n=271; eribulin, vinorelbine, capecitabine, or gemcitabine). The patients had received at least one previous endocrine therapy, a taxane, as well as a CDK4/6 inhibitor in any setting and 2-4 previous chemotherapy regimens for metastatic disease. The study's primary endpoint was progression-free survival while the secondary endpoints included objective response rate (ORR), overall survival, and patient-reported outcomes.
At the end of the study, it was observed that sacituzumab govitecan significantly improved overall survival. Also, ORR was significantly improved with sacituzumab govitecan as was time to deterioration of global health status and quality of life. The safety profile of sacituzumab govitecan was in accordance with those of the ASCENT trial and primary analysis of TROPiCS-02.
Based on the results of this study, it can be concluded that sacituzumab govitecan may be used as a new treatment option for patients with pretreated metastatic breast cancer as it may demonstrate statistically significant and clinically meaningful benefits with a manageable safety profile.